ARHGEF2 and myeloid leukemia: GEF-H1 (ARHGEF2). The reduction with siRNA of this Rho GEF in myeloid leukemia cells resulted in reduction of the motility of the cells, but not in their directional response in response to a gradient of fMLF (receptor FPR1) (105).